Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development. For ...

This is the only biotech stock to attract an investment from artificial intelligence (AI) giant Nvidia. Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, ...

Recursion Pharmaceuticals has an innovative, AI-focused approach to developing drugs. However, the company has yet to find tangible success and faces several headwinds. The stock has substantial ...